Apaluside 60mg Tablet

Apaluside 60mg tablet is a prescription based medication which is highly used medication in advanced prostate cancer in adult men. The medication is a selective androgen receptor (AR) inhibitor, that binds directly to the androgen (testosterone). It inhibits the formation of protein which is responsible for the production of cancer cells and reduces cancer cell growth or increases cell death. Apalutamide is an active ingredient of Apaluside responsible for these anti-cancer effects. Doctor supervision is needed in the treatment to ensure correct dosage and monitor for side effects.

Treat advanced prostate cancer in adult men.

● Brain tumor
● Diabetes
● Head injury
● Heart disease
● High blood pressure
● High cholesterol
● Osteoporosis, weak bones
● Seizures
● Stroke

Apaluside tablet should be taken orally in 60mg concentration. Take the medicine with or without food at the same time everyday. Dose adjustment may be required in patients with severe liver impairment or those experiencing significant adverse effects. Patient should be monitored for signs of prostate cancer progression, liver function and overall health status.

Apalutamide works by binding to the androgen receptor in prostate cancer cells and blocking the production of testosterone which is responsible for growing cancer cells in the body. This action inhibits the signaling pathways that drives the growth and proliferation of prostate cancer cells. This helps slow the progression of the disease, induces apoptosis of malignant cells, thereby contributing to improved clinical outcomes in patients with advanced prostate cancer.

• Chi, K. N., Agarwal, N., Bjartell, A., Chung, B. H., Pereira de Santana Gomes, A. J., Given, R., ... & Chowdhury, S. (2019). Apalutamide for metastatic, castration-sensitive prostate cancer. New England Journal of Medicine, 381(1), 13-24.
• Smith, M. R., Saad, F., Chowdhury, S., Oudard, S., Hadaschik, B. A., Graff, J. N., ... & Small, E. J. (2021). Apalutamide and overall survival in prostate cancer. European urology, 79(1), 150-158.
• Smith, M. R., Saad, F., Chowdhury, S., Oudard, S., Hadaschik, B. A., Graff, J. N., ... & Small, E. J. (2018). Apalutamide treatment and metastasis-free survival in prostate cancer. New England Journal of Medicine, 378(15), 1408-1418.
• Rathkopf, D. E., & Scher, H. I. (2018). Apalutamide for the treatment of prostate cancer. Expert review of anticancer therapy, 18(9), 823-836.
• Al-Salama, Z. T. (2018). Apalutamide: first global approval. Drugs, 78(6), 699-705.